Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease by Coletto, Erika et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/s41531-019-0081-9
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Coletto, E., Dolan, J. S., Pritchard, S., Gant, A., Hikima, A., Jackson, M. J., ... Iravani, M. M. (2019). Contractile
dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease. Nature
Parkinson's Journal, 5, [31231674]. https://doi.org/10.1038/s41531-019-0081-9
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
ARTICLE OPEN
Contractile dysfunction and nitrergic dysregulation in small
intestine of a primate model of Parkinson’s disease
Erika Coletto1, John S. Dolan2, Sara Pritchard2, Alex Gant2, Atsuko Hikima1, Michael J. Jackson1, Christopher D. Benham2,
K. Ray Chaudhuri3, Sarah Rose1, Peter Jenner1 and Mahmoud M. Iravani 2
Bowel dysfunction is a common non-motor symptom in Parkinson’s disease (PD). The main contractile neurotransmitter in the GI
tract is acetylcholine (ACh), while nitric oxide (NO) causes the relaxation of smooth muscle in addition to modulating ACh release.
The aim of this study was to characterise functional and neurochemical changes in the isolated ileum of the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated marmoset, an established model of PD motor dysfunction. While NO-synthase inhibitor L-
NAME concentration dependently augmented the neurogenically-evoked contractions and inhibited the relaxations in normal
tissues, it had no effects on the MPTP ileum. Immunohistochemical analyses of the myenteric plexus showed that ChAT-
immunoreactivity (-ir) was significantly reduced and the density of the enteric glial cells as shown by SOX-10-ir was increased.
However, no change in TH-, 5-HT-, VIP- or nNOS-ir was observed in the MPTP tissues. The enhancement of the neurogenically-
evoked contractions and the inhibition of the relaxation phase by L-NAME in the control tissues is in line with NO’s direct relaxing
effect on smooth muscle and its indirect inhibitory effect on ACh release. The absence of the relaxation and the inefficacy of L-
NAME in the MPTP tissues suggests that central dopaminergic loss dopamine may eventually lead to the impairment of NO signal
coupling that affects bowel function, and this may be the result of a complex dysregulation at the level of the neuroeffector
junction.
npj Parkinson’s Disease            (2019) 5:10 ; https://doi.org/10.1038/s41531-019-0081-9
INTRODUCTION
Parkinson’s disease (PD) encompasses a variety of motor and non-
motor symptoms. Autonomic dysfunction particularly of the
gastrointestinal tract (GI), is a common non-motor problem in
PD that may precede motor symptoms by more than 10 years
before individuals are diagnosed.1 Difficulties in swallowing,
constipation, dysphagia, and delayed gastric emptying and
reduced gastric motility are core components of this dysautono-
mia which may get worse as the disease progresses.
GI dysfunction in PD may have a central origin subsequent to
the degeneration of nigro-striatal dopaminergic neurones or an
intrinsic origin at the level of the enteric nervous system. A range
of enteric neurotransmitters/neuromodulators including acetylcho-
line (ACh), serotonin (5-HT), dopamine (DA), noradrenaline (NA),
vasoactive intestinal peptide (VIP) and nitric oxide (NO) control
smooth muscle activity. However, it is not clear whether single or
multiple neurotransmitters are involved in the control of the
smooth muscle contractility and gut motility or how these change
in relation to PD. Rodent studies using unilateral 6-OHDA lesioning
of the dopaminergic nigro-striatal tract have overall shown no
significant change in the level of ChAT-immunoreactivity (-ir)
throughout the GI tract following 6-OHDA in the rat2–4 or in the
MPTP-treated primate model of PD.5 An increase in VIP-ir and a
decrease in nNOS-ir was detected3,4 in the 6-OHDA rat model while
in the MPTP treated mouse no change in either NADPH-diaphorase
staining or ChAT-ir was observed compared to the controls—
although the level of TH-ir was reduced in the myenteric plexus of
the ileum.6 In contrast to the rodent studies, in the MPTP treated
primate,5 an increase in nNOS-ir in the myenteric plexus and the
submucosal plexus of the colon was observed. So, species-related
differences and their differing sensitivity to MPTP or to a more
targeted central 6-OHDA-induced dopaminergic lesion may con-
tribute to the pattern of change observed.
In contrast, very little is known about small-intestine motility in
PD. To date only a few studies have investigated colonic motility in
experimental models of the disease2–4,6–10 and no study has so far
investigated the functional consequences of nigro-striatal dopa-
minergic neuronal loss in the small intestine of either rodents or
primates. Colon is the main site of water and solute absorption
which in addition to dysmotility contribute to constipation, but
few studies have looked at the ileum where poor gastric transit is
thought to be a contributory factor to constipation.11,12 The
present study investigates the spontaneous contractile and
neurogenically driven contractile and the relaxant responses of
the isolated common ileum in normal and MPTP-treated common
marmoset. Alterations in response have been correlated to
changes in those neurotransmitters and neuromodulators
involved in contractile and relaxant responses. An important aim
was to study the impact of NOS inhibition on the contractile
response of the normal and MPTP-treated marmoset ileum
following neurogenic stimulation using electrical field stimulation
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as NO is considered to be a key player in the control of both the
contractile and relaxant.13–15
RESULTS
MPTP-induced loss of TH-ir in the nigrostriatal tract
There was marked loss of tyrosine hydroxylase immunoreactivity
(TH-ir) in both the substantia nigra (SN) and in the nerve terminal
regions in the MPTP-treated animals (Fig. 1a–f). Following MPTP
treatment the TH-ir neurones in the SN were significantly reduced
by approximately 70% (P < 0.0001, unpaired t-test n= 5–6). The
TH-ir in the caudate nucleus and the putamen were similarly
affected (P < 0.0001; one-way ANOVA, F= 3,22; caudate, n= 7;
MPTP putamen, n= 3–7).
Effect of agonists on contractile response
There was no significant difference in the concentration
dependent contraction to carbachol of both normal and MPTP
ileum preparations (Fig. 1g). The carbachol concentration
response curve produced LogEC50 of −6.641 to −5.755 and
−6.558 to −6.128 for the normal and MPTP ileum, respectively.
Similarly, cumulative application of histamine (100 nM to 100 µM)
produced concentration dependent contraction of both normal
and MPTP ileum but compared to carbachol the contractions were
markedly smaller in magnitude. No difference in histamine
concentration response curves was seen between the normal
and the MPTP tissues with LogEC50 of −6.68 to −3.636 and −6.58
to −4.371 for the normal and MPTP ileum, respectively (Fig. 1h).
The slopes of the carbachol and histamine concentration/
response were however different regardless of the animal
treatment.
Noradrenaline and dopamine agonists effects on spontaneous
activity
Administration of noradrenaline (NA, 10 µM) produced relaxation
of the basal resting tone of the smooth muscle in both normal and
MPTP ileum. In the normal ileum samples, NA reduced the
baseline by −0.5 ± 0.09 while in the MPTP ileum baseline
reduction was −0.3 ± 0.07 g, but this difference was not statisti-
cally significant (P= 0.116; n= 7).
The frequency of spontaneous contractions of ileum was
significantly increased by 30–40% following MPTP treatment
(Fig. 1i) but the amplitude was non-significantly reduced (Fig. 1d).
Administration of NA, dopamine D1 agonist, A77636 (1 µM) or D2
Agonist, ropinirole (1 µM) did affect the frequency of spontaneous
contractions of normal or MPTP ileum. However, only NA
significantly reduced the amplitude of the spontaneous contrac-
tions in both normal and MPTP ileum (Fig. 1j). There were no
differences between the effect of NA on the normal or MPTP
tissues.
Overall there was a positive correlation between motor
disability (see Table 1) and a negative correlation between the
number of TH-ir and the frequency of spontaneous activity.
However, in the latter this relationship failed to reach statistical
significance (P= 0.0589; Fig. 1k, l).
Effect of NOS-inhibitors on EFS-evoked contractile responses
Figure 2a–f shows representative response of normal and MPTP
ileum to EFS at 10 s trains of pulses, at 10 Hz (50 V, 0.2 ms pulse
width), the normal, control ileum produced a complex pattern of
contraction/relaxation (Fig. 2a) which were composed of three
distinct phases: phase-i: sharp contraction followed by phase-ii,
long-lasting relaxation and phase-iii, and a tonic, slowly develop-
ing after contraction. Only, the initial phase-i was completely
blocked by 3 µM atropine but phases-ii and -iii were unaffected
(Fig. 2b). Combined administration of 3 µM atropine and 100 µM L-
NAME completely blocked phases-i and -ii (Fig. 2c). In the ileum
obtained from MPTP-treated marmosets, a similar contractile
pattern was observed (Fig. 2d–f) but the relaxation component
was almost absent (Fig. 2e). When the EFS-evoked responses at
frequencies ranging from 1 to 60 Hz were examined, there was an
overall frequency dependent increase in the phase-i responses in
the tissues obtained from MPTP-treated animals, which at
frequencies greater than 20 Hz were significantly greater with
respect to the control tissues (Fig. 3g; P= 0.0049, F(1–70)= 8.44;
n= 6, 2-way ANOVA).
In response to EFS-evoked relaxation (phase-ii), the control
ileum relaxation was evident only at frequencies higher than 2 Hz
and these were maintained at 60 Hz. However, there was not a
clear frequency dependent relaxation response (Fig. 3h; P= 0.116,
F(6,70)= 1.78; n= 6, 2-way ANOVA). In stark contrast to the normal
tissues, the phase-ii responses of the ilea from the MPTP-treated
animals were absent at all frequencies of stimulation examined
beyond 2 Hz (P < 0.0001; F(1,70)= 50.28, n= 6, 2-way ANOVA).
When the phase-iii responses were examined, there was a clear
frequency-related enhancement of this late-appearing ‘after-
contraction’ but there was no difference in the magnitude of
the response between the control and the MPTP tissues (Fig. 2i).
Administration of NOS inhibitor L-NAME concentration depen-
dently increased the force of contraction highly significantly in the
normal ileum preparations (Fig. 3a; P= 0.0004; F(3,140)= 6.40, n=
6, 2-way ANOVA). However, in the tissues from the MPTP-treated
animals L-NAME had no significant effect overall (Fig. 3b; P=
0.506; F(3,140)= 0.78; n= 6, 2-way ANOVA). When the relaxant
component of the response (phase-ii) was investigated, it was
shown that L-NAME concentration dependently inhibited the
phase-ii responses only in the tissues obtained from the normal
animals (Fig. 3; P= 0.0003; F(3,140)= 6.81; n= 6, 2-way ANOVA) but
in those obtained from the MPTP-treated animals very little EFS-
evoked relaxation was seen. Instead, L-NAME at higher (>100 µM)
concentration seemed to reverse the relaxation to modest
contractions (Fig. 3d). However, the effect of L-NAME on phase-ii
component did not quite reach the level of significance (P=
0.0541; F(3,140)= 2.61, n= 6, 2-way ANOVA).
There was a frequency-related increase in the magnitude of the
phase-iii ‘after contractions’. However, L-NAME at any concentra-
tion used had no effect on tissues obtained either from the normal
or the MPTP-treated animals (Fig. 3e; control: P= 0.0765; F(3,140)=
2.33; Fig. 3f; MPTP: P= 0.504; F(3,140)= 0.79; n= 6; 2-way ANOVA).
Immunohistochemical analysis of myenteric plexus
Samples of proximal and distal ileum from normal and MPTP-
treated animal showed that there was no significant difference
in the total number of neurones as assessed by counting the
total number HuC/HuD immunoreactivity per ganglia/mm2. This
was a consistent pattern of observation from all samples studied
(Figs 4–6). In the proximal ileum, no difference was observed
between the number of ChAT-ir neurones colocalised with HuC/
HuD-ir neurones in the normal and MPTP tissues (Fig. 4g).
However, the number of normal controls were too few to allow
meaningful statistical analysis. In the distal ileum however, there
was a modest but highly significant reduction of the number of
ChAT-ir neurones (Fig. 4c–f) that were colocalised with HuC/HuD
in MPTP tissues (Fig. 4h; P= 0.0005; two-tailed Student’s
unpaired t-test n= 5–7).
When we compared the number of nNOS-ir and VIP-ir neurones
in the proximal (Fig. 5a) and the distal (Fig. 5b) ileum of normal
and MPTP-treated animals, we found that majority, but not all, of
the nNOS-ir and VIP-ir neurones were colocalised in both the
normal (Fig. 5A[a–d], B[a–d]) and MPTP (Fig. 5A[e–h], B[e–h]) ilea.
Since there were a few nNOS-ir and VIP-ir neurones that were not
colocalised, cell counts were therefore expressed as individual
counts for nNOS-ir and VIP-ir respectively or when nNOS-ir and
E. Coletto et al.
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VIP-ir were colocalised. The cell count data for the proximal and
distal ilea are shown in Fig. 5c, d, respectively. There was no
difference in the total number of nNOS-ir neurones in the
proximal or the distal ileum of the MPTP-treated animal (Fig. 5c,
P= 0.0795; unpaired Student’s t-test; n= 4–5; Fig. 5d, P= 0.312,
n= 6). The number of colocalised nNOS/VIP-ir was counted, were
smaller in both normal and MPTP of both proximal and distal ilea,
but there were no significant differences between them (Fig. 5c,
P= 0.921, n= 4–5; Fig. 5d, P= 0.0813, n= 6).
We also looked at the pattern of distribution of TH-ir in the
myenteric plexus. TH-ir was localised to fine fibres surrounding the
Huc/HuD-ir cells in the proximal (Fig. 5E[b–f]) and distal ileum
E. Coletto et al.
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(Fig. 5F[b–f]). There was a generalised reduction in the intensity of
TH-ir staining following MPTP (Fig. 5E[f], F[f]), but it was not
possible to accurately quantify the extent of reduction of TH-ir
using the currently used protocols. Triple labelling for HuC/HuD-ir,
TH-ir and nNOS-ir in both proximal and distal ileum showed that
TH-ir fibres surrounded some of the HuC/HuD-ir cells, a few of
which were also nNOS-ir. There was no difference in the number
of HuC/HuD-ir neurones that were associated with TH-ir and the
number of Huc/HuD-ir neurones that were colocalised with nNOS
and were associated with TH-ir fibres and were not different in the
proximal and the distal ilea of the MPTP-treated animals (Fig. 5g, h,
respectively).
In a similar fashion to TH-ir, 5-HT-ir fibres also finely arborised
around HuC/HuD-ir cells within the myenteric plexus ganglia in
the proximal (Fig. 6A[b–f]) and distal ileum (Fig. 6B[b–f]). Many but
not all 5-HTir fibres were associated with Huc/HuD cells in both
regions of normal and MPTP ileum. However, unlike TH-ir, no
evidence of any change in 5-HT-ir fibres was observed in different
regions and following MPTP treatment.
Using a SOX-10 antibody, a reliable marker of the enteric glial
cells,14 we found extensive immunoreactivity in the distal ileum
but there was no colocalisation of SOX-10-ir with HuC/HuD-ir cells
in any region investigated (Fig. 6E[a–d]). However, when the
number of SOX-10-ir cells were counted, there was a modest but
statistically significant increase in SOX-10-ir in the distal ileum
myenteric plexus of the MPTP-treated animals (Fig. 6E[e]). Not
enough samples were available to perform SOX-10-ir in the
proximal ileum.
DISCUSSION
Gut dysmotility is a common problem in PD and it can be
reproduced in several rodent and primate models of PD where the
dopaminergic nigro-striatal pathway has been destroyed.1,6–9
However, very little is known about the mechanisms that initiate
the abnormalities in the motility of the gastrointestinal tract.
Because toxin-induced ablation of the nigrostriatal tract in animals
results in similar gut dysfunction to that seen in PD, a role for the
central dopaminergic system is suggested that may in turn induce
an indirect effect on the dorsal motor nucleus of vagus and vagal
outflow. Indeed, direct administration of 6-OHDA into the
dopaminergic SN results in the loss of cholinergic and nitrergic
neurones in the dorsal vagal complex.8 Alternatively, direct
alterations in gut function and morphology may occur as
pathological markers associated with PD, in the form of α-
synuclein accumulations, are present in the gut.
Indeed, the results of the present study suggest that there are
marked local contractile changes occurring in the gut following
MPTP-treatment of common marmosets. The changes in contrac-
tility did not appear to be due to altered receptor–effector coupling
as the responsiveness to the cholinergic agonist, carbachol and to
histamine or to the relaxing effects of NA did not differ between the
tissues obtained from the control and the MPTP treated animals.
Using the EFS parameters chosen, a range of contractile responses
could be seen. The primary phasic contraction which was blocked
entirely by atropine (phase-i) was therefore deemed to be entirely
cholinergic; a later appearing relaxation which was blocked almost
entirely by the NOS-inhibitor L-NAME, so with a high level of
confidence this component was attributed to the generation and
the release of NO (phase-ii). The after-contraction response (phase-
iii) is more difficult to explain. While the magnitude of the delayed
contractile response appeared to be frequency dependent, but lack
of modulation of these responses by either atropine or L-NAME
suggested that the combination of excitatory and inhibitory
transmitters was not involved. It is plausible that the after-
contraction may be due to physiological adjustments of the
longitudinal smooth muscle cells following EFS-induced release of
excitatory and inhibitory neurotransmitters. However, interestingly
the lack of significant differences between the tissues from the
normal and the MPTP animals suggest that the observation of the
Fig. 1 The relationship between nigrostriatal tract TH-ir and contractile responses of the ileum. The effect of MPTP treatment on TH-ir in the
substantia nigra (SN, a, b, e) and the caudate nucleus and putamen c, d, f and the effect of lesioning on agonist evoked and spontaneous
contractile response of ileum. MPTP treatment resulted in marked reduction of TH-ir neurones e and TH-ir nerve terminals in the caudate
nucleus and the putamen f. Agonist evoked and spontaneous contractile responses of the normal, drug naive ileum (open data points) and
the ileum obtained from MPTP (shaded data points) treated common marmosets. Administration of carbachol g and histamine h evoked a
concentration dependent contraction of the isolated ileum which were not significantly different between the normal ileum and those from
MPTP treated animals. However, the frequency of spontaneous activity was significantly larger in preparations obtained from MPTP animals i
while the amplitude of spontaneous contractions appeared lower j although this reduction did not reach statistical significance.
Administration of noradrenaline (NA) or D1 (A77636) or D2 (ropinirole) agonists affected the frequency and the amplitude of the spontaneous
contractions similarly. Panels k and l show correlation between the frequency of contraction (number of contraction/min) and motor disability
k and the number of TH-ir neurones in the SN. Each bar is the mean ± s.e.m. of n= 7. *P < 0.05; **P < 0.001; ***P < 0.0005
Table 1. The details of common marmosets used in the study
Animal ID Sex Treatment Survival (days)
following MPTP
Peak motor
disability score
KCL14 Female N n/a 0
H26 Female N n/a 0
Y007 Male N n/a 0
X046 Male N n/a 0
Y107 Female N n/a 0
9094 Male N n/a 0
9102 Female N n/a 0
KCL10 Female MPTP 202 12.0
KCL4 Male MPTP 169 11.0
Px48 Female MPTP 1123 9.0
8036 Female MPTP 494 11.0
X036 Male MPTP 169 14.0
XO53 Male MPTP 521 15.0
XO78 Male MPTP 358 14.0
This table shows animal identification tags, their sex, their treatment and
survival time following MPTP treatment (0.2 mg/kg for 5 consecutive days)
and their peak stable motor disability. Basal motor disability was assessed
during the 1 h acclimatisation period using an established motor disability
rating scale: alertness (normal 0, sleepy 2); reaction (normal 0, reduced 1,
slow 2, absent 3); checking movements (present 0, reduced 1, absent 2);
attention and eye movements (normal 0, abnormal 1); posture (normal 0,
abnormal trunk +1, abnormal limbs +1, abnormal tail +1, or grossly
abnormal 4); balance/co-ordination (normal 0, impaired 1, unstable 2,
spontaneous falls 3); vocalisation (normal 0, reduced 1, absent 2); motility
(normal 0, bradykinesia/hyperkinesia 1, akinesia/hyperkinesia 2).30 A
maximum score of 18 indicated a high degree of motor disability and a
score of 0 indicated normal behaviour. The end of the survival time, is
when animals were terminally anaesthetised and the ilea and brains were
dissected
E. Coletto et al.
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differences in phase-1 and phase-ii responses were not due to the
differences in muscular mass of ilea from these animals.
At frequencies of stimulation higher than 20 Hz, the ilea from
the MPTP-treated animals contracted to a significantly greater
extent compared to the controls and the relaxation in response to
EFS was virtually absent at all stimulation frequencies. Both
observations could easily be explained by the loss of intrinsic
nitrergic transmission. It has previously been shown that in normal
guinea-pig ileum, inhibition of nitric oxide synthase could have
two important effects: Firstly, inhibition of NO synthesis which will
not only prevent the NO-mediated relaxation12 but may also
indirectly enhance EFS-evoked contractile response because the
contribution to EFS to contraction will likely result from release of
both excitatory (ACh) and inhibitory (NO) and inhibition of NO
synthesis will allow only the expression of the effects of the
excitatory neurotransmitter. Secondly, NO has been shown to
inhibit ACh release,13–16 so inhibition of NOS will allow more EFS-
evoked released of ACh. There are several possible explanations as
to why the contractile responses at higher EFS frequencies might
be greater in the MPTP tissues. Since EFS is likely to depolarise all
nerve endings indiscriminately, then increasing the strength of
stimulation at higher frequencies is likely to recruit deeper and
finer nerve inhibitory fibres more readily. Activation of these fibres
may release both NO or another inhibitory neurotransmitter VIP
which in turn would control ACh release. Because these fibres may
require more intense stimulation, then dysfunction of these fibres
following MPTP treatment would reveal the enhanced contraction
at higher EFS frequencies only in the MPTP ileum. Thus, we
propose that the dysfunction of the nitrergic transmission is the
likely cause of enhanced contractile response of the longitudinal
smooth muscle of the ileum following MPTP. That, phase-ii
responses were already inhibited at all stimulation frequencies,
suggest that NO may indeed have two distinct functions as stated
above. Another evidence for nitrergic dysfunction following MPTP
comes from the effects of L-NAME. The NOS inhibitor L-NAME
concentration dependently potentiated the phase-i contractions
Fig. 2 Characterisation of EFS-evoked contractile and relaxant responses of isolated common marmoset ileum. Representative traces showing
the contractile response of isolated ileum from normal, drug naive (a–c) and MPTP treated common marmoset (d–f) in response electrical field
stimulation and their pharmacological manipulation. Contraction elicited by 10 s trains of pulses at 10 Hz produced triphasic contractions a:
initial contraction (phase-i) followed by a later appearing relaxation (phase-ii) and a slow developing contraction following the relaxation
response (phase-iii). Phases i and ii were atropine b and L-NAME c sensitive, respectively. In tissues obtained from the MPTP treated animals
component ii was markedly reduced (d–f). Panels (g–i) summarise the contractile and relaxation responses to EFS at differences stimulation
frequencies: g phase-i; h phase-ii; i phase-iii. Small horizontal bars indicate the duration of EFS. Each bar is the mean ± s.e.m. of n= 6. *P < 0.05;
**P < 0.001; ***P < 0.0005
E. Coletto et al.
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of the control tissue, again at frequencies above 20 Hz to a similar
magnitude as the MPTP tissues, but in the absence of L-NAME.
However, L-NAME had no effect on the phase-i response of the
tissues from MPTP treated animals. Moreover, the EFS-evoked
phase-ii relaxation of the control tissues was also concentration
dependently inhibited by L-NAME had no effect on the phase-ii
response of the MPTP ileum. Indeed, there was some evidence of
rebound contraction as the concentration of L-NAME was
increased. Nitrergic dysfunction in PD is not unprecedented.
One interesting parallel which circumstantially supports the
notion of nitrergic dysfunction in PD is the occurrence of erectile
dysfunction in PD17 which in a similar to gut dysfunction can be
ameliorated by apomorphine. However, since the intrinsic
neurotransmitter involved in penile erection is NO, then and
inhibition of the phosphodiesterase-V can enhance the effects of
the residual levels of NO on cyclic GMP could reverse erectile
dysfunction. Consequently, agents such as sildenafil that enhance
the level of cyclic GMP might have some utility in the treatment of
bowel dysfunction in PD. Indeed, recently the efficacy of sildenafil
in normalising gut transit in a mouse model of constipation has
been demonstrated.18
Similar contractile and relaxant responses to the present study
was also reported earlier in the colon of MPTP treated mice6 but
curiously, the authors of that study compared the mechanical
response of the colon with NADPH-diaphorase staining in the
ileum and they could not find any loss of nitrergic innervation in
the myenteric plexus. However, this was in contrast to a study in 6-
OHDA lesioned rats9 where the contractile response and ChAT-ir
of isolated colon was reduced compared to controls. Interestingly,
a study comparing the neurotransmitter phenotypes along the GI
tract of macaques and human and another in PD showed a
significant overlap between NOS and VIP along the myenteric
Fig. 3 Contribution of nitrergic transmission to EFS-evoked contractile and relaxant responses of common marmoset ileum. The effect of L-
NAME on the EFS-evoked contractile and relaxation response of the normal, drug naive (a, c, e) and MPTP-treated (b, d, f) common marmoset
ileum. L-NAME concentration dependently increased the phase-i contractile response in normal a but had no effect on the ilea of the MPTP-
treated animals b. The phase-i and the phase-ii relaxation was concentration dependently inhibited by L-NAME in the normal c but in tissues
from the MPTP-treated animals, EFS-evoked relaxation was absent d. The phase-iii contractile response in tissues from normal e and MPTP-
treated f were similar in magnitude but L-NAME did not have any significant effect on the EFS-evoked responses. Each bar is the mean ± s.e.m.
of n= 6. *P < 0.05; **P < 0.001
E. Coletto et al.
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plexus of these two species, but there was an increasing gradient
in the expression of NOS-ir neurones from the stomach down to
the rectum.19,20 However, this gradient was reversed for ChAT-ir.19
This finding strongly suggests that the expression of different
neurotransmitters is not uniform and any findings with regards to
the extent of cholinergic and nitrergic innervation in the ileum
does not apply to the colon. Moreover, those studies suggest that
locations along the GI tract where samples are taken greatly
influences the observed expression of various neurotransmitter
markers. Thus, it might be the reason why different results have
been seen in different studies. For this reason, we only looked at
the expression of several neurotransmitters along the proximal
and distal ileum and consequently what we found cannot be
extrapolated to the colon where most of the previous investiga-
tions were conducted.
In confirmation of earlier study in PD20 we found no evidence of
loss of myenteric ganglion neurones as revealed by Huc/HuD-ir
and in confirmation of the findings of Anderson et al.,6 in the
MPTP-treated mice and the intranigral 6-OHDA administration8 we
found that the expression of ChAT-ir was significantly reduced
only in the distal ileum of the MPTP-treated animals, from where
the tissues samples used for the functional study were obtained.
Our VIP-ir and NOS-ir studies showed that nearly all VIP-
immunoreactivity was colocalised with NOS. However, most
interestingly we found no change following MPTP treatment in
either the NOS-ir or the VIP-ir in any part of the ileum suggesting
that the inhibitory transmitters were completely intact. This
finding also mirrored the observations made in MPTP treated
mice,6 MPTP-treated primates5 and in human PD.20 This finding is
quite intriguing because our functional data clearly suggested that
there is an impairment of the nitrergic system following MPTP
treatment found no evidence of alterations in NOS-ir. Anderson
et al.6 suggested that the enhanced contraction and the impaired
relaxation of the smooth muscle of colon from MPTP-treated mice
in response to EFS may result from the loss dopaminergic
innervation of the myenteric plexus. Since TH-ir was confined, at
least in this case to fine nerve fibres, it was very difficult to
quantify any changes following MPTP. Consequently, we counted
all the Huc/HuD-ir neurones that were closely associated with TH-
ir. Based solely on qualitative observation of the TH-ir alone, there
was an indication of reduced intensity of TH-ir fibres in the
myenteric plexus, but when the association of TH-ir fibres with
Huc/HuD-immunoreactive cells were assessed we found no
significant difference between tissues obtained from the normal
and MPTP-treated animals. Moreover, compared to other neuro-
transmitters, very little dopamine is present in the myenteric
plexus. Although there is evidence that in neurotoxin-induced
parkinsonism in rodent and in PD there is a distinct loss
dopaminergic innervation5,6,21–23 but this finding has not been
consistent.20 Consequently, we feel that the role of dopamine in
the observed contractile response of the MPTP ileum is unlikely.
There was far more 5-HT-ir fibres associated with HuC/HuD fibres
compared to TH-ir but again there was no difference in 5-HT-ir
fibres between the normal and the MPTP ilea.
Chaumette et al.5 showed that there was no change following
MPTP treatment in the enteric glial inflammatory marker, SOX-1024
in macaques. Their assessment was based on counting the
number of SOX-10-ir cells within the myenteric ganglia from four
animals. Here, in 5 control and 6 MPTP animals we found a modest
but statistically significant increase in the number of SOX-10-ir
cells, which suggested that MPTP treatment led to inflammation
of the ileum. While it is known that in the brain or in the ileum, EFS
evokes NO release14,15,25 and inflammatory cells in the brain
(microglia and astrocytes) are also an important source of nitric
oxide,26,27 but it is not known whether EFS is likely to cause the
release of non-neuronal NO from either the brain or the enteric
Fig. 4 The effect of MPTP treatment on expression of cholinacetyltransferase-immunoreactivity (ChAT-ir) in myenteric plexus of ileum.
Quantitative analysis of HuC/HuD and ChAT-ir in the whole-mount myenteric plexus preparations from normal, drug naive a, b, c and MPTP-
treated d, e, f animals. The number of HC/HuD is unchanged in proximal g and distal h ileum. In the proximal ileum h, ChAT-ir is unchanged
but it is significantly reduced in the distal ileum myenteric plexus g; ***P < 0.0005. Scale bar (d) represents 100 µm
E. Coletto et al.
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glial cells. Moreover, NOS-inhibitors currently do not have
sufficient selectivity to distinguish the contribution of different
iso-forms of NOS towards NO release. Consequently, on the
balance of probabilities, EFS-evoked release of NO from eNOS or
iNOS is unlikely.
In conclusion, the pharmacological results of this study that the
contractile response of the longitudinal smooth muscle of the
ileum is significantly larger and the relaxation is absent in
response to EFS strongly suggests that central dopaminergic
denervation following MPTP treatment leads to dysregulation of
nitrergic transmission, which will indirectly enhance the contrac-
tion of the longitudinal muscle but will prevent it from relaxing.
This has the effect of disrupting peristaltic movement which is
likely to slow down gut motility. However, there is a caveat to the
interpretation of the data in that we have not monitored the
peristaltic activity and using this experimental set up we can only
draw the conclusions related only to the activity of the
longitudinal muscle. Thus, the effect of MPTP-treatment on the
activity of the circular muscle in this animal model remains
untested and unknown. Nevertheless, the importance of ileal
dysmotility in the onset of constipation cannot be ignored as
several studies have indicated that ileum is involved11,12 although
pathologies that lead to slow transit constipation are similar in
both ileum and colon.28 The clinical correlates of these changes, if
Fig. 5 The effect of MPTP treatment on expression of VIP-ir, nNOS and TH-ir in myenteric plexus of ileum. Quantitative analysis of HuC/HuD
and co-localisation of VIP- and nNOS-immunoreactivity (A[a–h], B[a–h]) and Tyrosine hydroxylase (TH)- and nNOS immunoreactivity (E[a–h]
and F[a–h]) in the whole mount myenteric plexus of proximal (A[a–h], E[a–h]) and distal (B[a–h], F[a–h]) and ileum preparation of normal,
drug naive and MPTP-treated animals. The number of HC/HuD is unchanged in proximal (c, g) and distal (d, h) ileum. The individual number of
nNOS-ir and VIP or the number of nNOS/VIP co-localisation and number of individual nNOS-ir and TH-ir or nNOS/TH-ir co-localisation was not
changed in the proximal and distal ileum following MPTP-treatment. Scale bars represent 50 µm (Aa) and 100 µm (Ee)
E. Coletto et al.
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any, are unknown, although the very uncomfortable sensation of
abdominal bloating experienced by some individuals with PD,
especially as an ‘off’ phenomenon, could be the consequence of
small-intestinal dysmotility.29 Further work would be needed to
tease out the mechanism(s) involved in this process.
METHODS
Animals
All experimental work was carried out in accordance with the Animals
(Scientific Procedures) Act 1986 approved by the Kings College London
Ethical Review Committee. In particular, the primate experiments reported
were subject to and were carried out under the Animals (Scientific
Procedures) Act 1986 under a Home Office Project Licence (PPL 70/4986)
approved by the King’s Ethical Committee which complied fully with the
guidelines and recommendations set out in the Weatherall Report 2006—
the use of non-human primates in research (https://royalsociety.org/policy/
publications/2006/weatherall-report/). The animals’ environment was
enriched by installation of viewing turret on top of the cages to mimic
height as would be the case in a normal habitat (height: 36 cm, width:
35 cm, depth: 50 cm) and wooden ladders/perches, Hammocks, swings,
nesting boxes, multiple feeding platforms and saw dusted floors for forage
feeding.
Two groups of normal controls (n= 7; 3 males and 4 females, 333–407 g;
373 ± 16 g) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP;
Sigma, Poole, UK)-treated (n= 7; 3 males and 4 females, 313–389 g;
359 ± 17 g) (MPTP, 5 × 2mg/kg s.c.) adult common marmosets (Callithrix
jacchus, Harlan UK Ltd. Loughborough, LE12 9TE, UK, Manchester
University and King’s College London) were used in this study. The
MPTP-treated animals were prepared according to the previously
published protocols30–32 and were used in other studies where the
symptomatic effects of various dopamine agonists were examined. MPTP-
lesioned animals were culled between 1 and 3 years after the end of MPTP
treatment, so there was no likelihood of the presence of residual MPTP.
The normal marmosets were completely drug and toxin naive. Similarly
treated animals exhibited greater than 70% loss of dopaminergic neurons
in the SN.33
All marmosets were kept in home cages with dimensions of height: 166,
width: 140 and depth: 90 cm at an ambient temperature of 25 ± 1 °C.
Animals were housed in home cages in pairs, as approved by the Home
Office inspectorate at King’s College London facilities, in a 12 h light/dark
cycle at an ambient temperature of 25 ± 1 °C and were fed once daily with
a diet of bananas, oranges and apples and had free access to food pellets
(Mini Marex-E; Special diet Services) and drinking water. The detail of
animals used and their motor disability scores as well as their survival time
after last MPTP treatment have been summarised in Table 1.
Fig. 6 The effect of MPTP treatment on serotonergic fibres and on immune cells in the myenteric plexus of ileum. Quantitative analysis of
HuC/HuD and 5-HT immunoreactivity (5-TH-ir) in the whole-mount myenteric plexus preparations from normal, drug naive (A[a–c], B[a–c])
and MPTP-treated (A[d–f], B[d–f]) animals. The number of HC/HuD is unchanged in proximal c and distal d ileum and MPTP treatment did not
affect the expression of 5-HT-ir expression in either region of the ileum. In e, quantitative analysis of HuC/HuD and SOX-10 immunoreactive
glial cells (SOX-10-ir) in the whole-mount myenteric plexus preparations from normal, drug naive and MPTP-treated distal ilea (a–d) is shown.
There was a similar number of HuC/HuD and SOX-ir cells in the myenteric plexus e but following MPTP treatment there was a modest but
significant increase in the number of SOX-ir; *P < 0.05. Each bar is the mean ± s.e.m. Scale bar represent 100 µm
E. Coletto et al.
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Organ bath studies
Common marmosets were killed using overdose of pentobarbital sodium
(60mg/kg; Euthatal, Merial Animal Health Ltd.) between 7:30 and 8:30 am.
Upon cessation of foot and corneal reflexes, the thoracic and abdominal
cavities were opened. The animals were transcardially perfused with ice-
cold oxygenated (95% O2 plus 5% CO2) Krebs–Henseleit solution
(composition in mM: NaCl 118, KCI 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25,
KH2PO4 1.2, glucose 11) and a length of the proximal to the distal ileum
before the start of the descending colon was excised and placed in this
solution. While still in aerated Krebs–Henseleit solution, four to five 2 cm
lengths of the ileum were cut transversely through the lumen. The
proximal and the distal segments saved for immunohistochemical analysis
and the middle portions were transported to the laboratory where they
were suspended in a 15ml organ baths and placed under a resting tension
of 1.0 g force at 37 °C. Following a 30–60min equilibration period, and
initiation of spontaneous contractions, the contractile activity of the ileum
was measured using an isometric transducer connected to LabChart data
acquisition system (AD Instruments Ltd., Oxford, UK).
Tissues viability was tested initially by the administration of carbachol
(CCH), 10 µM to access the contractile responses. Only tissues that
contracted >2 g tension were included in the study. To assess whether
prior MPTP treatment affected the receptor/effector coupling or whether
there were changes at the level of smooth muscle, the isolated ileum
preparations were contracted by cumulative addition of various concen-
trations of CCh (0.01–30 µM; Sigma-Aldrich) or histamine (0.1–100 µM;
Sigma-Aldrich). Tissues were then thoroughly washed with several changes
of Kreb’s solution and subsequently the relaxant effect of noradrenaline
(NA) was then compared on the amplitude, tone and the frequency the
spontaneous contractile response of the ileum from naive and MPTP-
treated animals. Since there is evidence for the presence of enteric
dopaminergic neurones34 that modulate intestinal motility, which might
be affected following MPTP-treatment, the effect of both dopaminergic D1
agonist, A77636 or D2 agonist ropinirole were tested on the tone,
amplitude and frequency of spontaneous rhythmic contractions of the
ileum preparation obtained from normal, drug naive or MPTP-treated
animals. The amplitude was estimated by adding together the tension of
individual contractions occurring during a period of 10min and dividing
this sum by the number of contractions during this period. The rate of
spontaneous activity (rate/min) was derived from dividing the total
number of contractions during the 10min observation period.
Electrical field stimulation induced contractions and relaxations
To assess any neurogenic alterations in the contractile and relaxant
responses following MPTP treatment, ileum preparations were contracted
indirectly by EFS delivered through a pair of platinum electrodes placed on
either side of the muscle strips in the organ bath. The ileal segments from
drug naive normal and MPTP-treated common marmosets were stimulated
with 10 s trains of pulses at 1.0, 2.0, 5.0, 10, 20, 40 and 60 Hz and pulse
duration of 0.2 ms at supramaximal voltage (50 V) once every 5min.
Contractile responses to EFS were evoked in the absence or in the
presence of 3 µM atropine (atropine sulphate, Sigma-Aldrich) to assess the
contribution of the cholinergic component to the EFS-evoked contractile
responses. Atropine was administered 30min before EFS-evoked
responses started. To investigate the contribution of the NO to the overall
contractile or relaxation responses following EFS, non-selective NOS
inhibitor, L-nitroarginine methyl ester (L-NAME) at concentrations ranging
10 µM to 1mM was added to the organ bath 15min before EFS was
effected.
Nigrostriatal TH-immunoreactivity
In order to ascertain the extent of MPTP-induced nigrostriatal lesions,
30 µm free-floating sections from the SN and the striatum were processed
for TH immunohistochemistry according to previously published proto-
col35 with some modifications regarding analysis of striatal TH+ve optical
density in the caudate nucleus and the putamen. Briefly, following
incubation with rabbit anti-TH antibodies (see Table 2) overnight at room
temperature. Following colour development, The TH-immunoreactive (ir)
neurones in the SN sections were manually counted. The number of TH-ir
neurones at the level of the third nerve was derived by averaging 3–4
adjacent sections (depending on availability of the relevant sections)
where the 3rd nerve rootlets were clearly identifiable. The striatal TH-ir at
different regions following MPTP treatment was assessed by densitometry
using Image-J software. Variations in staining intensity within the caudate
and the putamen were assessed. To normalise for variation in staining
intensity, a reading was obtained from the white matter in the corpus
callosum and this was subtracted from readings obtained within the
caudate nucleus and the putamen.
Intestinal whole mount preparation
Proximal and distal segments of ileum were immersed for 15min in 0.1 M
phosphate buffered saline (PBS) pH 7.2 containing 1 µM nicardipine as a
muscle relaxant (Sigma-Aldrich, UK). Sections were then opened along the
mesenteric line and washed in PBS to remove the content of the lumen.
Subsequently, the proximal and distal ileum preparations were stretched
on a wax support with the mucosa layer facing downwards and fixed for
6/7 h in Zamboni’s fixative (2% paraformaldehyde containing 0.2% picric
acid in 0.1 M PBS) at 4 °C. Following fixation, the tissues were removed
from the wax support and washed in dimethylsulfoxide (DMSO) followed
by three 10min washes in PBS and then stored at 4 °C in PBS containing
0.1% sodium azide (Sigma-Aldrich). Stretch specimens were processed as
longitudinal muscle-myenteric plexus whole mount preparations (LMMPs)
by peeling away the different layers (i.e. mucosa, submucosa and circular
muscle) as previously described.2
To analyse the enteric neurons in the myenteric plexus of the LMMPs,
double staining (Hu/Chat, Hu/5-HT, Hu/Substance P and Hu/GFAP) or triple
labelling (Hu/VIP/nNOS, Hu/TH/nNOS) immunofluorescence techniques
were performed. Depending on the antibody characteristics either the
immunofluorescence histochemistry, or labelled streptavidin–biotin (LSAB)
methods were used.
Double staining procedures
Prior to immunostaining, whole mount samples were permeabilised for 1 h
at room temperature in blocking buffer containing 1% Triton X-100 (10%
normal goat or donkey serum in 0.1 M PBS) to reduce non-specific binding.
Whole mounts were then incubated overnight in mixtures of primary
antibodies diluted in the blocking buffer, at 4 °C. Anti-Huc/HuD antibody
was used to identify all myenteric neuronal cell bodies.36 Details of all
primary antibodies used are summarised in Table 1. Whole mounts were
then washed with PBS, and incubated with secondary antibodies diluted in
the blocking buffer for 3 h at room temperature. The tissue preparations
were then washed 3 × 10min in PBS and then mounted onto slides using
Table 2. The detail of primary antibodies used in this study and their host sources
Primary antibodies Host Dilution Source
Neuronal protein Huc/HuD—monoclonal Mouse 1:50 16A11; Molecular Probes
Vasoactive intestinal Polypeptide (VIP)—polyclonal Rabbit 1:100 Sc-20727; Santa Cruz Biotechnology
Neuronal nitric oxide synthase (nNOS)—polyclonal Rabbit 1:500 AB76442; Millipore
Tyrosine hydroxylase (TH)—polyclonal Chicken 1:400 AB76442; Abcam
Tyrosine hydroxylase (TH)—polyclonal Rabbit 1:1000 AB112; Abcam
Choline acetyl transferase (ChAT)—polyclonal Goat 1:20 AB144P; Millipore
Serotonin (5-HT)—polyclonal Rabbit 1:1000 PC228L; Merck Chemicals
SOX-10—polyclonal Goat 1:100 Sc-17342; Santa Cruz Biotechnology
E. Coletto et al.
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Mowiol mounting media (Mowiol 40-88 Sigma 324590, Tris Buffer 0.2 M pH
8.5, distilled water, Glycerol, DABCO-Sigma D-2522, Sodium Azide 10%
stock).
The labelled streptavidin–biotin (LSAB)
After staining with primary antibody, tissues were washed in PBS and then
incubated with biotinylated secondary antibody, diluted in the blocking
buffer, for 1 h at room temperature. Whole mount preparations were then
incubated overnight with a second primary antibody following the same
procedure for time and temperature. After 24 h, specimens were washed in
PBS and incubated in fluorescent dye streptavidin and suitable secondary
antibody for 3 h, then washing and mounting as described above.
The details of all the primary antibodies used and their sources are
summarised in Table 2.
Cell counting
Image capture was performed using a Zeiss ApoTome microscope and a
Zeiss AxioCam camera. Images were captured by Zeiss AxioVision 4.0
image analysis software. Whole-mount preparations were used to perform
a quantitative analysis of the different neuronal populations investigated
(ChAT-ir, nNOS-ir, VIP-ir, 5-HT-ir, TH-ir and SOX-10-ir) with respect to the
HuC/HuD-ir neuronal population. All observations were made at ×20
objective. Firstly, the number of neuronal cells counted within each
ganglion in the myenteric plexus and this usually had an area of between
0.02 and 0.04mm2 and approximately a total of about 250–300 HuC/HuD-
ir neurones were counted from randomly selected ganglia. Normally
5 slides were counted per animal sample. Average counts for each animal
was then normalised to total counts/mm2.
Data analysis and statistics
For the amplitude and the frequency of spontaneous contractions, and the
EFS-evoked contractions or relaxations at different stimulation frequencies
the values for the replicates running in parallel (n= 2–3) were averaged for
each animal and presented as n= 1. The overall mean ± s.e.m. was
determined from the individual average values of all animals in their
respective groups. Where multiple groups of data in concentration
response curves or where the contractile or relaxant responses to different
stimulation frequencies were compared, a two-tailed, two-way ANOVA
followed by Fisher’s LSD multiple comparison post hoc test was used. For
comparison of cell counts and immunohistochemical analyses expressed
as total counts/mm2 were means expressed as mean ± s.e.m. and the
differences between naive controls and MPTP samples were compared
using an un-paired, two-tailed Student’s t-test. Where there was a
correlation of dopaminergic cell loss with motor behaviour or gut function,
data were analysed using a one-tailed Pearson’s r correlation. All statistical
analyses were carried out using Prism 6.0 software (GraphPad, San Diego,
CA USA). Differences were considered statistically significant at P < 0.05.
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